France's Stentys is celebrating more positive clinical data stemming from the use of its self-apposing stent to treat acute heart attacks.
The industry has descended on Paris to talk stents, valves and drug elution at EuroPCR, touting new technologies to an audience of the world's cardiovascular decisionmakers. Check out the highlights from Day Three >>
Boston Scientific made a splash when it spent $425 million on 2012 Fierce 15 winner Vessix Vascular last year, and now, with strong interim data for its newly acquired renal denervation system, the company has a shot to compete for market share in the soon-to-boom space.
Covidien is celebrating results from a trial showing one of its ablation therapy devices helped prevent an advance to esophageal cancer by eliminating a precancerous condition known as Barrett's esophagus.
A who's who of medical device outfits have taken to Paris this week for EuroPCR, flaunting their latest data and devices to a gathering of the continent's interventional cardiovascular specialists. Here's a look at the highlights from Day Two >>
EuroPCR kicked off in Paris on Tuesday, bringing devicemakers from around the globe together to unveil data and angle for attention from the continent's interventional cardiovascular specialists. Here's a look at some early highlights from the conference.
Medtronic snagged a CE mark for the Export Advance aspiration catheter, planning to launch the clot-removing device in Europe and other international markets.
Boston Scientific enrolled its first patient in a study of its self-expanding WallFlex Biliary RX Stent to broaden the indication of the device for the purposes of draining bile before pancreatic cancer surgery.
St. Jude Medical's much-scrutinized defibrillator leads remained almost 100% safe from abrasion and mechanical failure after 5 years, according to an independent analysis, results the company hopes will quiet alarm from regulators and competitors.
Boston Scientific's Watchman is more effective in preventing stroke than standard-of-care warfarin, according to a study, giving the company some renewed hope for the device's FDA approval and eventual large market leadership.